Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609.
Laurie E McLouthYue ZhengStephanie SmithF Stephen HodiUma N RaoGary I CohenThomas T AmatrudaShaker R DakhilBrendan D CurtiIbrahim NakhoulSreenivasa R ChandanaCharles L BaneDavid E MarinierSandra J LeeVernon K SondakJohn M KirkwoodAhmad A TarhiniLynne I WagnerPublished in: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2022)
NCT01274338, January 11, 2011 (first posted date) https://clinicaltrials.gov/ct2/show/NCT01274338?term=NCT01274338&draw=2&rank=1 .
Keyphrases
- phase iii
- open label
- patient reported
- high dose
- double blind
- placebo controlled
- clinical trial
- phase ii
- early stage
- low dose
- study protocol
- preterm infants
- computed tomography
- dendritic cells
- lymph node
- image quality
- stem cell transplantation
- contrast enhanced
- dual energy
- magnetic resonance imaging
- replacement therapy
- pet ct
- skin cancer